BiotechTV - News
BiotechTV
This is the primary news channel of BiotechTV where you will find on the ground reporting by our journalists from biotech hubs throughout the world.
Episodes
Mentioned books
Oct 14, 2025 • 8min
Benchtalk 2025: Generate:Biomedicines' VP of Informatics Stephen Kottmann describes the investments in technology that ensures only the highest quality data returns back into its models
He walks us through the design, build, test, learn model that is the foundation of Generate's approach to drug development.
Oct 14, 2025 • 5min
Benchtalk 2025: Benchling Co-Founder & CEO Sajith Wickramasekara describes why he believes science and Benchling are entering a new era of speed and cost of R&D
He welcomes us to Benchtalk 2025, which had more than 800 scientists register this year, and describes how AI and other computational advances are allowing scientists to focus on increasing the speed and reducing the cost of R&D.
Oct 14, 2025 • 10min
Benchtalk 2025: Dyne Therapeutics' CSO Ron Batra describes the company's FORCE platform, and previews big trial scheduled in DMD and DM1 over the next year
He describes the science behind FORCE, which combines an antigen-binding fragment, a linker and, a payload. The company's DMD program will have a key trial readout before the end of this year, and DM1 will follow in 2026. Both programs could be filed for AA in 2026 with positive data.
Oct 10, 2025 • 13min
Sunrise Group, which has designed a mandibular sensor for at-home diagnosis of sleep apnea, recently raised $29M to expand its digital sleep clinic that patients can access remotely
Co-Founder & CEO Laurent Martinot discusses the raise, and the need for more accessible sleep health care. Plus, previewing a clinical trial of its device that will read out shortly.
Oct 10, 2025 • 17min
Oxford's OrganOx became one of the UK's biggest news stories when it was announced it would be acquired by Japan's Terumo for approximately $1.5 billion - here's the revolutionary technology behind it
CEO Craig Marshall describes how the company's "metra" device pumps blood through donor organs (currently livers) in order to extend the amount of time they can be transplanted safely.
Oct 9, 2025 • 13min
Oxford, UK based OMass Therapeutics, experts in the use of mass spectrometry in drug development, recently landed a $20M up front licensing deal with Roche on one of its preclinical candidates for IBF
CEO Ros Deegan discusses the deal and the path to getting there, and she highlights some of OMass' other programs the company is driving forward alone, including an MC2 antagonist. Plus, the company's unique expertise in the use of mass spec.
Oct 9, 2025 • 7min
NYSE Market Strategist Eric Criscuolo discusses biotech's newfound momentum and whether it might attract generalists to take a look at the sector
He discusses the rally biotech has had of late, and that was boosted by Pfizer's deal with the White House. Plus, how interest rates, employment, and other factors are affecting the broader economy, and might impact biotech.
Oct 9, 2025 • 23min
Immuneering's CEO walks us through the company's MEK data in pancreatic cancer, and explains the science behind 'deep cyclic inhibition'
Ben Zeskind describes the company's 9 month follow-up for atebimetinib + mGnP, which showed 86% overall survival and 53% progression free survival.
Oct 8, 2025 • 41min
R.W. Baird Managing Director & Senior Biotech Analyst Brian Skorney discusses numerous battleground companies in biotech
He shares his thoughts on Soleno, Sarepta, Lexeo, Enanta, Crinetics, Vertex, Xenon, and more.
Oct 8, 2025 • 16min
Biotech veteran David Hung talks about the launch of IBTROZI in ROS1 positive non-small cell lung cancer, and what's next for Nuvation Bio
He discusses the clinical profile of IBTROZI, how the launch is going, and describes other work the company is doing in precision medicine. Plus, his take on the biotech environment currently.
